Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Depreciation and Depletion (2016 - 2025)

Iradimed (IRMD) has disclosed Depreciation and Depletion for 13 consecutive years, with $256315.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion rose 83.29% to $256315.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $661688.0, a 7.73% increase, with the full-year FY2024 number at $585542.0, down 9.66% from a year prior.
  • Depreciation and Depletion was $256315.0 for Q3 2025 at Iradimed, up from $135670.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $256315.0 in Q3 2025 to a low of $127139.0 in Q1 2021.
  • A 5-year average of $150623.2 and a median of $141697.0 in 2024 define the central range for Depreciation and Depletion.
  • Biggest YoY gain for Depreciation and Depletion was 83.29% in 2025; the steepest drop was 20.34% in 2025.
  • Iradimed's Depreciation and Depletion stood at $135997.0 in 2021, then increased by 9.99% to $149581.0 in 2022, then increased by 9.67% to $164039.0 in 2023, then dropped by 17.49% to $135348.0 in 2024, then skyrocketed by 89.37% to $256315.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Depreciation and Depletion are $256315.0 (Q3 2025), $135670.0 (Q2 2025), and $134355.0 (Q1 2025).